Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Orally administered lanthanum carbonate (Fosrenol) dissociates in the acid environment of the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary phosphate. Lanthanum carbonate was effective in reducing levels of serum phosphate and serum calcium x phosphate
A conventional human pharmacokinetic (PK) in vivo study is often considered as the "gold standard" to determine bioequivalence (BE) of drug products. However, this BE approach is not always applicable to the products not intended to be delivered into the
Ecotoxicology and environmental safety, 104, 152-159 (2014-03-29)
The enhanced ultraviolet-B (UV-B) radiation caused by ozone depletion may exert deleterious effects on plants. Therefore, studies on the effect of UV-B radiation on plants, as well as studies on the methods for alleviating the deleterious effects by chemical control
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
